Phase III trial investigating the efficacy of an encapsulated cell therapy product [NovaCaps] versus gemcitabine for advanced, inoperable pancreatic cancer

Trial Profile

Phase III trial investigating the efficacy of an encapsulated cell therapy product [NovaCaps] versus gemcitabine for advanced, inoperable pancreatic cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs Microencapsulated CYP2B1-expressing cells PharmaCyte Biotech (Primary) ; Gemcitabine; Ifosfamide
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors PharmaCyte Biotech
  • Most Recent Events

    • 24 Oct 2016 According to a PharmaCyte Biotech media release, Manuel Hidalgo, MD, PhD has agreed to serve as the Principal Investigator for this trial.
    • 04 Nov 2013 Cloning of the cancer-drug-activating cells required for phase 3 clinical trials has begun at Inno Biologics, according to a Nuvilex media release.
    • 19 Sep 2013 Inno Biologics will generate cell clones for production of microencapsulated CYP-2B1-expressing cells for this trial, and Fisher BioServices will store them, according to a Nuvilex media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top